221 related articles for article (PubMed ID: 33891473)
21. Relevance of baseline carcinoembryonic antigen for first-line treatment against metastatic colorectal cancer with FOLFIRI plus cetuximab or bevacizumab (FIRE-3 trial).
Holch JW; Ricard I; Stintzing S; Fischer von Weikersthal L; Decker T; Kiani A; Vehling-Kaiser U; Heintges T; Kahl C; Kullmann F; Scheithauer W; Moehler M; Jelas I; Modest DP; Westphalen CB; von Einem JC; Michl M; Heinemann V
Eur J Cancer; 2019 Jan; 106():115-125. PubMed ID: 30496943
[TBL] [Abstract][Full Text] [Related]
22. Randomized phase III trial in elderly patients comparing LV5FU2 with or without irinotecan for first-line treatment of metastatic colorectal cancer (FFCD 2001-02).
Aparicio T; Lavau-Denes S; Phelip JM; Maillard E; Jouve JL; Gargot D; Gasmi M; Locher C; Adhoute X; Michel P; Khemissa F; Lecomte T; Provençal J; Breysacher G; Legoux JL; Lepère C; Charneau J; Cretin J; Chone L; Azzedine A; Bouché O; Sobhani I; Bedenne L; Mitry E;
Ann Oncol; 2016 Jan; 27(1):121-7. PubMed ID: 26487578
[TBL] [Abstract][Full Text] [Related]
23. First-line mFOLFOX plus cetuximab followed by mFOLFOX plus cetuximab or single-agent cetuximab as maintenance therapy in patients with metastatic colorectal cancer: Phase II randomised MACRO2 TTD study.
Aranda E; García-Alfonso P; Benavides M; Sánchez Ruiz A; Guillén-Ponce C; Safont MJ; Alcaide J; Gómez A; López R; Manzano JL; Méndez Ureña M; Sastre J; Rivera F; Grávalos C; García T; Martín-Valadés JI; Falcó E; Navalón M; González Flores E; Ma García Tapiador A; Ma López Muñoz A; Barrajón E; Reboredo M; García Teijido P; Viudez A; Cárdenas N; Díaz-Rubio E;
Eur J Cancer; 2018 Sep; 101():263-272. PubMed ID: 30054049
[TBL] [Abstract][Full Text] [Related]
24. Regorafenib in Patients with Antiangiogenic-Naïve and Chemotherapy-Refractory Advanced Colorectal Cancer: Results from a Phase IIb Trial.
Riechelmann RP; Leite LS; Bariani GM; Glasberg J; Rivelli TG; da Fonseca LG; Nebuloni DR; Braghiroli MI; Queiroz MA; Isejima AM; Kappeler C; Kikuchi L; Hoff PM
Oncologist; 2019 Sep; 24(9):1180-1187. PubMed ID: 31175167
[TBL] [Abstract][Full Text] [Related]
25. AtezoTRIBE: a randomised phase II study of FOLFOXIRI plus bevacizumab alone or in combination with atezolizumab as initial therapy for patients with unresectable metastatic colorectal cancer.
Antoniotti C; Borelli B; Rossini D; Pietrantonio F; Morano F; Salvatore L; Lonardi S; Marmorino F; Tamberi S; Corallo S; Tortora G; Bergamo F; Brunella DS; Boccaccino A; Grassi E; Racca P; Tamburini E; Aprile G; Moretto R; Boni L; Falcone A; Cremolini C
BMC Cancer; 2020 Jul; 20(1):683. PubMed ID: 32698790
[TBL] [Abstract][Full Text] [Related]
26. Mutational Analysis of Patients With Colorectal Cancer in CALGB/SWOG 80405 Identifies New Roles of Microsatellite Instability and Tumor Mutational Burden for Patient Outcome.
Innocenti F; Ou FS; Qu X; Zemla TJ; Niedzwiecki D; Tam R; Mahajan S; Goldberg RM; Bertagnolli MM; Blanke CD; Sanoff H; Atkins J; Polite B; Venook AP; Lenz HJ; Kabbarah O
J Clin Oncol; 2019 May; 37(14):1217-1227. PubMed ID: 30865548
[TBL] [Abstract][Full Text] [Related]
27. Eligibility of real-world patients with chemo-refractory, K-RAS wild-type, metastatic colorectal cancer for palliative intent regorafenib monotherapy.
Angeles A; Hung W; Cheung WY
Med Oncol; 2018 Jun; 35(8):114. PubMed ID: 29936654
[TBL] [Abstract][Full Text] [Related]
28. Real-world survival outcomes of heavily pretreated patients with refractory HR+, HER2-metastatic breast cancer receiving single-agent chemotherapy-a comparison with MONARCH 1.
Rugo HS; Dieras V; Cortes J; Patt D; Wildiers H; O'Shaughnessy J; Zamora E; Yardley DA; Carter GC; Sheffield KM; Li L; Andre VAM; Li XI; Frenzel M; Huang YJ; Dickler MN; Tolaney SM
Breast Cancer Res Treat; 2020 Nov; 184(1):161-172. PubMed ID: 32789591
[TBL] [Abstract][Full Text] [Related]
29. Phase III trial of cetuximab with continuous or intermittent fluorouracil, leucovorin, and oxaliplatin (Nordic FLOX) versus FLOX alone in first-line treatment of metastatic colorectal cancer: the NORDIC-VII study.
Tveit KM; Guren T; Glimelius B; Pfeiffer P; Sorbye H; Pyrhonen S; Sigurdsson F; Kure E; Ikdahl T; Skovlund E; Fokstuen T; Hansen F; Hofsli E; Birkemeyer E; Johnsson A; Starkhammar H; Yilmaz MK; Keldsen N; Erdal AB; Dajani O; Dahl O; Christoffersen T
J Clin Oncol; 2012 May; 30(15):1755-62. PubMed ID: 22473155
[TBL] [Abstract][Full Text] [Related]
30. Emulating Randomized Controlled Trials with Hybrid Control Arms in Oncology: A Case Study.
Sengupta S; Ntambwe I; Tan K; Liang Q; Paulucci D; Castellanos E; Fiore J; Lane S; Micsinai Balan M; Viraswami-Apanna K; Sethuraman V; Samant M; Tiwari R
Clin Pharmacol Ther; 2023 Apr; 113(4):867-877. PubMed ID: 36606735
[TBL] [Abstract][Full Text] [Related]
31. A randomized study of KRAS-guided maintenance therapy with bevacizumab, erlotinib or metronomic capecitabine after first-line induction treatment of metastatic colorectal cancer: the Nordic ACT2 trial.
Hagman H; Frödin JE; Berglund Å; Sundberg J; Vestermark LW; Albertsson M; Fernebro E; Johnsson A
Ann Oncol; 2016 Jan; 27(1):140-7. PubMed ID: 26483047
[TBL] [Abstract][Full Text] [Related]
32. Propensity Score Weighting Using Overlap Weights: A New Method Applied to Regorafenib Clinical Data and a Cost-Effectiveness Analysis.
Mlcoch T; Hrnciarova T; Tuzil J; Zadak J; Marian M; Dolezal T
Value Health; 2019 Dec; 22(12):1370-1377. PubMed ID: 31806193
[TBL] [Abstract][Full Text] [Related]
33. Integrating real world data and clinical trial results using survival data reconstruction and marginal moment-balancing weights.
Getz K; Mamtani R; Hubbard RA
J Biopharm Stat; 2022 Jan; 32(1):191-203. PubMed ID: 34756156
[TBL] [Abstract][Full Text] [Related]
34. aCGH Analysis of Predictive Biomarkers for Response to Bevacizumab plus Oxaliplatin- or Irinotecan-Based Chemotherapy in Patients with Metastatic Colorectal Cancer.
Fujita Y; Taguri M; Yamazaki K; Tsurutani J; Sakai K; Tsushima T; Nagase M; Tamagawa H; Ueda S; Tamura T; Tsuji Y; Murata K; Taira K; Denda T; Moriwaki T; Funai S; Nakajima TE; Muro K; Tsuji A; Yoshida M; Suyama K; Kurimoto T; Sugimoto N; Baba E; Seki N; Sato M; Shimura T; Boku N; Hyodo I; Yamanaka T; Nishio K
Oncologist; 2019 Mar; 24(3):327-337. PubMed ID: 30425180
[TBL] [Abstract][Full Text] [Related]
35. Effect of Bevacizumab in Combination With Standard Oxaliplatin-Based Regimens in Patients With Metastatic Colorectal Cancer: A Randomized Clinical Trial.
Avallone A; Piccirillo MC; Nasti G; Rosati G; Carlomagno C; Di Gennaro E; Romano C; Tatangelo F; Granata V; Cassata A; Silvestro L; De Stefano A; Aloj L; Vicario V; Nappi A; Leone A; Bilancia D; Arenare L; Petrillo A; Lastoria S; Gallo C; Botti G; Delrio P; Izzo F; Perrone F; Budillon A
JAMA Netw Open; 2021 Jul; 4(7):e2118475. PubMed ID: 34309665
[TBL] [Abstract][Full Text] [Related]
36. Large-Scale, Prospective Observational Study of Regorafenib in Japanese Patients with Metastatic Colorectal Cancer in a Real-World Clinical Setting.
Yamaguchi K; Komatsu Y; Satoh T; Uetake H; Yoshino T; Nishida T; Yamazaki N; Takikawa H; Morimoto T; Chosa M; Sunaya T; Hamada Y; Muro K; Sugihara K
Oncologist; 2019 Jul; 24(7):e450-e457. PubMed ID: 30606885
[TBL] [Abstract][Full Text] [Related]
37. Primary Tumor Resection and Overall Survival in Patients With Metastatic Colorectal Cancer Treated With Palliative Intent.
Wong SF; Wong HL; Field KM; Kosmider S; Tie J; Wong R; Tacey M; Shapiro J; Nott L; Richardson G; Cooray P; Jones I; Croxford M; Gibbs P
Clin Colorectal Cancer; 2016 Sep; 15(3):e125-32. PubMed ID: 26803709
[TBL] [Abstract][Full Text] [Related]
38. Outcome of chemotherapy with or without targeted agents in metastatic colorectal cancer patients with deficient DNA mismatch repair: A single center, cohort study.
Yu Y; Ying J; Zhang W; Li W; Sun Y; Yang L; Cui C; Zeng Y; Zhou A
Asia Pac J Clin Oncol; 2019 Jun; 15(3):128-135. PubMed ID: 30693649
[TBL] [Abstract][Full Text] [Related]
39. Aflibercept and Docetaxel versus Docetaxel alone after platinum failure in patients with advanced or metastatic non-small-cell lung cancer: a randomized, controlled phase III trial.
Ramlau R; Gorbunova V; Ciuleanu TE; Novello S; Ozguroglu M; Goksel T; Baldotto C; Bennouna J; Shepherd FA; Le-Guennec S; Rey A; Miller V; Thatcher N; Scagliotti G
J Clin Oncol; 2012 Oct; 30(29):3640-7. PubMed ID: 22965962
[TBL] [Abstract][Full Text] [Related]
40. Treatment sequence with either irinotecan/cetuximab followed by FOLFOX-4 or the reverse strategy in metastatic colorectal cancer patients progressing after first-line FOLFIRI/bevacizumab: An Italian Group for the Study of Gastrointestinal Cancer phase III, randomised trial comparing two sequences of therapy in colorectal metastatic patients.
Cascinu S; Rosati G; Nasti G; Lonardi S; Zaniboni A; Marchetti P; Leone F; Bilancia D; Iaffaioli RV; Zagonel V; Giordano M; Corsi DC; Ferraú F; Labianca R; Ronzoni M; Scartozzi M; Galli F;
Eur J Cancer; 2017 Sep; 83():106-115. PubMed ID: 28735067
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
